Drug
Tucatinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | HER(2) targeting TKI |
| Mechanism of Action | HER2 inhibitor |
| Half-life | 16.2 h - 21.3 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in HER2-overexpressing tumors (↓HER2/AKT/ERK, delayed DSB repair, ↑apoptosis/senescence) without sensitizing HER2-negative cells (Amrell et al., Cancer Cell International, 2024; Yu et al., Oncotarget, 2016). Antigen/driver-restricted sensitization limits theoretical field side-effects, though the pan-HER class effect of diarrhea and mucocutaneous adverse events could overlap with RT-related GI/mucosal reactions.
Data on this page refer exclusively to patients treated with
Tucatinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
HER(2) targeting TKI group page.